1. Rise of cGMP by partial phosphodiesterase-3A degradation enhances cardioprotection during hypoxia
- Author
-
Nadja I. Bork, Anna Kuret, Melanie Cruz Santos, Cristina E. Molina, Beate Reiter, Hermann Reichenspurner, Andreas Friebe, Boris V. Skryabin, Timofey S. Rozhdestvensky, Michaela Kuhn, Robert Lukowski, and Viacheslav O. Nikolaev
- Subjects
Cardiomyocyte cGMP ,FRET biosensor ,Hypoxia ,Ischemia/reperfusion ,Phosphodiesterase ,Medicine (General) ,R5-920 ,Biology (General) ,QH301-705.5 - Abstract
3′,5′-cyclic guanosine monophosphate (cGMP) is a druggable second messenger regulating cell growth and survival in a plethora of cells and disease states, many of which are associated with hypoxia. For example, in myocardial infarction and heart failure (HF), clinical use of cGMP-elevating drugs improves disease outcomes. Although they protect mice from ischemia/reperfusion (I/R) injury, the exact mechanism how cardiac cGMP signaling is regulated in response to hypoxia is still largely unknown. By monitoring real-time cGMP dynamics in murine and human cardiomyocytes using in vitro and in vivo models of hypoxia/reoxygenation (H/R) and I/R injury combined with biochemical methods, we show that hypoxia causes rapid but partial degradation of cGMP-hydrolyzing phosphodiesterase-3A (PDE3A) protein via the autophagosomal-lysosomal pathway. While increasing cGMP in hypoxia prevents cell death, partially reduced PDE3A does not change the pro-apoptotic second messenger 3′,5′-cyclic adenosine monophosphate (cAMP). However, it leads to significantly enhanced protective effects of clinically relevant activators of nitric oxide-sensitive guanylyl cyclase (NO-GC). Collectively, our mouse and human data unravel a new mechanism by which cardiac cGMP improves hypoxia-associated disease conditions.
- Published
- 2021
- Full Text
- View/download PDF